Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Bladder Cancer Resource Center

News
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024

Stephanie Holland

Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
From Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
From Oncology
David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023

Featuring David Bogumil

Featuring David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
Guideline Updates
NCCN Updates Therapy Guidelines in Bladder Cancer
08/26/2022

Yvette C Terrie

Yvette C Terrie
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for Bladder Cancer presented data evaluating new treatment options in bladder cancer, as well as relevant updates to the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer.
NCCN Guidelines Panel for...
08/26/2022
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022

Ellen Kurek

Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
Research Reports
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
05/18/2021
Richard G Stefanacci, DO
Jason Yeaw, MPH
Drishti Shah, PhD
Amy Kincaid, MA
Paul N Mudd Jr, PharmD, MBA
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and colleagues describe and evaluate the population, treatment patterns, HCRU, and costs associated with overactive bladder in the in the US long-term care setting.
Richard Stefanacci, DO, and...
05/18/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/24/2021

Janelle Bradley

Janelle Bradley
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical practice guideline for bladder cancer, removing atezolizumab as an alternative second-line systemic therapy option for locally advanced or metastatic disease.
NCCN updated its clinical...
03/24/2021
Journal of Clinical Pathways
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Bladder Cancer
Guideline Updates
NCCN Updates Clinical Practice Guideline for Bladder Cancer
03/10/2021
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for bladder cancer.
On March 9, 2021, the National...
03/10/2021
Journal of Clinical Pathways
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways

Advertisement

Expert Insights

David Bogumil
Videos
Multiple Ethnicities Study Explores A Connection Between Type 2 Diabetes and Urinary Bladder Cancer
10/12/2023

Featuring David Bogumil

Featuring David Bogumil
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his findings on a connection between type 2 diabetes and urinary bladder cancer for African American, European American, Japanese American, Latin American, and Native Hawaiian populations.
David Bogumil, PhD, details his...
10/12/2023
Journal of Clinical Pathways
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
Videos
Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma
03/12/2021
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.
Nimira Alimohamed, MD, discusses...
03/12/2021
Journal of Clinical Pathways
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
Videos
Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma
02/19/2021
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Shilpa Gupta, MD, discusses the...
02/19/2021
Journal of Clinical Pathways
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
Videos
Adoption of Avelumab for First-Line Maintenance Therapy of Urothelial Cancer in US
02/18/2021
02/18/2021
Journal of Clinical Pathways
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
Videos
Pembrolizumab Unlikely Cost-Effective for BCG-Unresponsive Bladder Cancer in US
02/17/2021
02/17/2021
Journal of Clinical Pathways
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
The Bear: Why Does Health Care Cost So Much? (Part 1)
05/06/2024

Featuring Michael Kolodziej, MD, and John Hennessy, MBA

Featuring Michael Kolodziej, MD, and ...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dig into two of the main stakeholders in health care costs: hospitals and health insurance companies. They discuss how these...
In part one of this two-part...
05/06/2024
Cancer Care Business Exchange
Julia Morton
Videos
The Impact of Technology at the Point of Care in Community Practice
05/01/2024
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice president and general manager at Flatiron Health, talks about how recent developments in technology have impacted point-of-care solutions in community oncology.
Julia Morton, senior vice...
05/01/2024
Journal of Clinical Pathways
JCP Flatiron Roundtable 1 Thumbnail
Videos
Oncology Care Pathways: Perspectives on Strategies and Best Practices
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Michael Serzan, MD
Videos
Recent Advancements in the Treatment of Renal Cell Carcinoma
04/24/2024

Featuring Michael Serzan, MD, Dana-Farber Cancer Institute

Featuring Michael Serzan, MD, Dana-Fa...
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights some of the latest advancements in the treatment of renal cell carcinoma.
Michael Serzan, MD, highlights...
04/24/2024
Journal of Clinical Pathways
Kerry Rogers, MD
Interview
Venetoclax Plus Ibrutinib Combination Therapy for Treating Patients With CLL With Resistance Mutations
04/19/2024

Featuring Kerry Rogers, MD, The Ohio State University

Featuring Kerry Rogers, MD, The Ohio ...
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State University, discusses results from her study on how Bruton tyrosine kinase (BTK) inhibitors ibrutinib and venetoclax could help eliminate molecular resistance in patients with CLL who have resistance mutations.
Kerry Rogers, MD, The Ohio State...
04/19/2024
Journal of Clinical Pathways
Rose Gerber, MS
Videos
Becoming a Patient Advocate: Tips for Getting Started
04/12/2024

Featuring Rose Gerber, MS

Featuring Rose Gerber, MS
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer survivor Rose Gerber shares her experience in cancer patient advocacy and offers tips for those who wish to become advocates.
Patient advocate and cancer...
04/12/2024
Journal of Clinical Pathways
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Erin Fox, PharmD
Videos
How Health Care Stakeholders in Oncology Can Prepare for and Manage Drug Shortages
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Robert Stillman, MA, RN
Videos
Best Practices in Care Team Communication Technology: Updates From NCCN 2024
04/06/2024

Featuring Robert Stillman, MA, RN

Featuring Robert Stillman, MA, RN ...
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN, describes some of the latest innovations in health care communications technology and how providers can use these tools to improve their practices and provide value-based care.
Robert Stillman, MA, RN,...
04/06/2024
Journal of Clinical Pathways

Newsfeed

News
FDA Approves Erdafitinib for Patients With Locally Advanced/Metastatic Urothelial Carcinoma Harboring FGFR3 Alterations
01/20/2024

Stephanie Holland

Stephanie Holland
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma
01/08/2024
Allison Casey
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.
According to a retrospective...
01/08/2024
Oncology
Conference Coverage
Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma
03/31/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).
At the 2023 ASCO GU Cancers...
03/31/2023
Journal of Clinical Pathways
News
Increased Costs Associated With Excessive Surveillance and Treatment For Non–Muscle-Invasive Bladder Cancer
04/14/2022

Ellen Kurek

Ellen Kurek
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost of care for low-grade, non–muscle-invasive bladder cancer increased by 60%, or nearly $20,000, from 2004 to 2013, according to a population-based cohort study.
The annual median one-year cost...
04/14/2022
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Grace Taylor, MS, MA
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Exploring Novel Therapies in Oncology: Lessons From the Oncology Care Model
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
04/11/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
04/11/2024
Journal of Clinical Pathways
AI
News
The Potential for AI in Oncology
04/11/2024
Grace Taylor, MS, MA
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay Doddamani, MD, MBA, provide an overview of where artificial intelligence technology stands today and how it comes into play within the oncology space.
Jim Chen, MD, and Sanjay...
04/11/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP March/April 2024

Current Issue

April 2024
Volume 10
Issue 2
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement